HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.

AuthorsR Tubiana, E Gomard, H Fleury, M L Gougeon, B Mouthon, H Picolet, C Katlama
JournalAIDS (London, England) (AIDS) Vol. 11 Issue 6 Pg. 819-20 (May 1997) ISSN: 0269-9370 [Print] England
PMID9143616 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • ALVAC vaccine
  • HIV Antibodies
  • HIV Core Protein p24
  • HIV Envelope Protein gp160
  • Vaccines, Synthetic
  • Viral Vaccines
Topics
  • Avipoxvirus
  • Consumer Product Safety
  • Double-Blind Method
  • Genetic Vectors
  • HIV Antibodies (blood)
  • HIV Core Protein p24 (blood)
  • HIV Envelope Protein gp160 (genetics, therapeutic use)
  • HIV Infections (blood, immunology, therapy, virology)
  • Humans
  • Immunogenetics
  • Immunotherapy, Active
  • Recombination, Genetic
  • Vaccines, Synthetic
  • Viral Load
  • Viral Vaccines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: